undamentalytics Newsletter
Sign in

Rallybio Corp revenue

Rallybio Corp's revenue was $858,000 in fiscal 2025, up 34.9% on the year before. Over the last twelve months it was $434,000.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMSept 2026
Revenue636858434
Growth on the year before—+34.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Collaboration and License Revenue $858,000 ▲ 34.9%
Licenses $800,000 ▲ 33.3%

These categories overlap or exclude eliminations, so shares aren't shown.

From Rallybio Corp's 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Rallybio Corp $434,000 -35.6% —
Cardiff Oncology, Inc. $508,000 -7.0% 7.2%
Cervomed Inc. $331,295 -95.7% -52.7%
Medicinova Inc $920,481 875.7% —
Clene Inc. $197,000 -31.1% -36.9%
Shattuck Labs, Inc. $1.0m -66.6% 5.2%

Compare with peers

Head to head: CRDF vs RLYBCRVO vs RLYBMNOV vs RLYB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Rallybio Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rallybio Corp.